J7601 HCPCS Level II code: Ensifentrine, inhalation suspension, fda approved final product, non-compounded, administered through dme, unit dose form, 3 mg
J7601 is the HCPCS code for “Ensifentrine, inhalation suspension, fda approved final product, non-compounded, administered through dme, unit dose form, 3 mg” in CMS’s October 2026 release, in effect from Oct 1, 2026.
Official description
J7601Ensifentrine, inhalation suspension, fda approved final product, non-compounded, administered through dme, unit dose form, 3 mg
Short description: Ensifentrine inh 3 mg
HCPCS · United States
Medicare details
The indicators CMS publishes with J7601 in its October 2026 file. They describe Medicare’s handling, not another payer’s.
- Medicare coverage
- Carrier judgment
- Medicare pricing
- Drugs
- Type of service
- Medical care; Lump sum purchase of DME, prosthetics, orthotics
- BETOS category
- Drugs Administered through DME
- Added
- Jan 1, 2025
Where J7601 sits
- 1J codesDrugs administered other than orally
- 2Active code J7601Ensifentrine, inhalation suspension, fda approved final product, non-compounded, administered through dme, unit dose form, 3 mg
Source and release
- Data release
- HCPCS Level II · October 2026
- Effective date
- Oct 1, 2026
- Publisher
- CMS
This page is built from the HCPCS Level II catalog that Vero Codes reads when it suggests codes: Centers for Medicare & Medicaid Services’s October 2026 release, imported from the publisher’s file and checked against it. The description, notes and structured data come from the same record.
Frequently asked questions
What does HCPCS code J7601 mean?
J7601 is the HCPCS code for “Ensifentrine, inhalation suspension, fda approved final product, non-compounded, administered through dme, unit dose form, 3 mg” in CMS’s HCPCS Level II October 2026 release.
Does Medicare cover J7601?
CMS lists J7601’s Medicare coverage as “Carrier judgment” and its pricing as “Drugs”. Coverage and payment still depend on the patient, the setting, the documentation and the payer.
Which HCPCS Level II release does this page use?
It uses CMS’s October 2026 release, in effect from Oct 1, 2026 to Dec 31, 2026. It is a reference: confirm the code against the current list and the payer’s rules before you submit it.
Codes beside J7601
All J codesJ7527Everolimus, oral, 0.25 mgJ7528Mycophenolate mofetil, for suspension, oral, 100 mgJ7529Mycophenolate mofetil, for suspension, oral, 5 mgJ7530Mycophenolate mofetil (myhibbin), oral suspension, 5 mgJ7531Prednisolone sodium phosphate, orally disintegrating tablet, 1 mgJ7599Immunosuppressive drug, not otherwise classifiedJ7604Acetylcysteine, inhalation solution, compounded product, administered through dme, unit dose form, per gramJ7605Arformoterol, inhalation solution, fda approved final product, non-compounded, administered through dme, unit dose form, 15 microgramsJ7606Formoterol fumarate, inhalation solution, fda approved final product, non-compounded, administered through dme, unit dose form, 20 microgramsJ7607Levalbuterol, inhalation solution, compounded product, administered through dme, concentrated form, 0.5 mgJ7608Acetylcysteine, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose form, per gramJ7609Albuterol, inhalation solution, compounded product, administered through dme, unit dose, 1 mg